Neutrophils engraftment delay during tigecycline treatment in 2 bone marrow-transplanted patients.
J Pediatr Hematol Oncol
; 35(1): e33-7, 2013 Jan.
Article
en En
| MEDLINE
| ID: mdl-23171996
ABSTRACT
BACKGROUND:
Tigecycline is the first available drug of glycylcycline family. Because of recent introduction, some of its adverse effects could be still unexplored. OBSERVATION We report the cases of 2 boys who underwent an allogenic bone marrow transplantation for acute myeloid leukemia and were treated with tigecycline. Erythrocyte and platelet engraftment followed a normal course, but the neutrophil count remained low despite the increase in leukocyte count. After tigecycline interruption, the neutrophil count rapidly raised in both cases.CONCLUSIONS:
Neutropenia was suspected to be secondary to tigecycline exposure. In vitro experiments were performed, which suggested tigecycline influence on myeloid cells survival.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Leucemia Mieloide Aguda
/
Trasplante de Médula Ósea
/
Células Mieloides
/
Minociclina
/
Antibacterianos
/
Neutropenia
/
Neutrófilos
Tipo de estudio:
Prognostic_studies
Límite:
Adolescent
/
Child
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
J Pediatr Hematol Oncol
Asunto de la revista:
HEMATOLOGIA
/
NEOPLASIAS
/
PEDIATRIA
Año:
2013
Tipo del documento:
Article
País de afiliación:
Italia